Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | LDHB | P07195 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11902557 | 0.86 | MEP1B (0.34) | ACLYTP53MAPTALDH1A1MEP1B | |
| SCHEMBL11903154 | 0.84 | ACLY (0.34) | ACLYTP53MAPTALDH1A1MEP1B | |
| SCHEMBL11902929 | 0.80 | TAS1R3 (0.33) | ACLYTP53MAPTALDH1A1MEP1B | |
| SCHEMBL1656975 | 0.79 | MEN1 (0.37) | ACLYMAPTALDH1A1MEP1BTAS1R3 | |
| SCHEMBL1654721 | 0.79 | CYP1A2 (0.43) | MAPTALDH1A1PPARG | |
| SCHEMBL1609808 | 0.78 | MAPT (0.33) | ACLYTP53MAPTALDH1A1MEP1B | |
| SCHEMBL117789 | 0.77 | TAS1R3 (0.40) | ACLYALDH1A1MEP1BTAS1R3TAS1R1 | |
| SCHEMBL11913397 | 0.76 | MEP1B (0.35) | ACLYMEP1BTAS1R3TAS1R1 | |
| SCHEMBL11913413 | 0.76 | MEN1 (0.38) | ACLYTP53MAPTALDH1A1TAS1R3 | |
| SCHEMBL2682965 | 0.75 | SMN1; SMN2 (0.40) | ACLYMAPTMEP1BTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202690-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202690-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202690-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202690-A1 | HERBICIDAL COMPOUNDS | DDT, HAO2, HAAO | ACLY 537/4885TP53 3431/4885MAPT 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.